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ARTICLE OPEN
Circulating cell-free mitochondrial DNA, but not leukocyte
mitochondrial DNA copy number, is elevated in major
depressive disorder
Daniel Lindqvist1,2,3, Owen M. Wolkowitz2, Martin Picard4,5,6, Lars Ohlsson7, Francesco S. Bersani2,8, Johan Fernström1,3, Åsa Westrin1,3,
Christina M. Hough2,11, Jue Lin9, Victor I. Reus2, Elissa S. Epel2 and Synthia H. Mellon10
Major depressive disorder (MDD) has been linked to mitochondrial defects, which could manifest in mitochondrial DNA (mtDNA)
polymorphisms or mutations. Additionally, copy number of mtDNA (mtDNA-cn) can be quantified in peripheral blood mononuclear
cells (PBMC)s, indirectly reflecting cellular energetics, or in the circulating cell-free mtDNA (ccf-mtDNA) levels, which may reflect a
fraction of the mitochondrial genome released during cellular stress. Few studies have examined ccf-mtDNA in MDD, and no
studies have tested its relationship with intracellular mtDNA-cn or with antidepressant treatment response. Here, mtDNA levels
were quantified in parallel from: (i) PBMCs and (ii) cell-free plasma of 50 unmedicated MDD subjects and 55 controls, in parallel with
PBMC telomere length (TL) and antioxidant enzyme glutathione peroxidase (GpX) activity. MtDNA measures were repeated in 19
MDD subjects after 8 weeks of open-label SSRI treatment. In analyses adjusted for age, sex, BMI, and smoking, MDD subjects had
significantly elevated levels of ccf-mtDNA (F = 20.6, p = 0.00002). PBMC mtDNA-cn did not differ between groups (p > 0.4). In
preliminary analyses, we found that changes in ccf-mtDNA with SSRI treatment differed between SSRI responders and non-
responders (F = 6.47, p = 0.02), with the non-responders showing an increase in ccf-mtDNA and responders not changing. Baseline
ccf-mtDNA was positively correlated with GpX (r = 0.32, p = 0.001), and PBMC mtDNA correlated positively with PBMC TL (r = 0.38,
p = 0.0001). These data suggest that plasma ccf-mtDNA and PBMC mtDNA-cn reflect different cellular processes and that the former
may be more reflective of certain aspects of MDD pathophysiology and of the response to SSRI antidepressants.
Neuropsychopharmacology (2018) 43:1557–1564; https://doi.org/10.1038/s41386-017-0001-9
INTRODUCTION
Mitochondrial dysfunction may be involved in the pathophysiol-
ogy of MDD [1–5]. Cells contain multiple mitochondria and, in
turn, each mitochondrion contains multiple copies of its own
genome, the mitochondrial DNA (mtDNA), which encodes 37
genes essential to energy production [6]. Mitochondria may be
conceptualized as the “power generators” of the cell, converting
oxygen, energy substrates (proteins, carbohydrates and lipids) and
other substrates into adenosine triphosphate [7]. Beyond energy
production, mitochondria generate other signaling molecules that
influence cellular and physiological functions, [8, 9] including
cellular senescence [10] and production of free radicals [11]. As a
result of these mechanisms, mitochondrial impairments may be
associated with, and/or lead to, psychiatric manifestations such as
mood and anxiety disorders, conditions that have been associated
with cellular senescence and oxidative stress. [12, 13]
mtDNA copy number (mtDNA-cn), which represents the
number of mitochondrial genomes per cell [6], can be quantified
in peripheral blood mononuclear cells (PBMC) and is thought to
reflect variations in mitochondrial energetic function and biogen-
esis [6]. Additionally, mtDNA may be released at low levels into the
circulation from mitochondria under cellular stress, resulting in
circulating cell-free mtDNA (ccf-mtDNA) detectable in plasma [14,
15]. Ccf-mtDNA has only very recently been assessed in psychiatric
patients after suicide attempt [16], and in MDD subjects [17].
Although the exact source or significance of ccf-mtDNA in
psychiatric illness is yet to be determined, it is suggested to
reflect cellular extrusion of mitochondria, during apoptotic or
necrotic cell death or other processes, resulting in mtDNA
appearing in the plasma [18, 19]. In addition, oxidative stress
may promote the release of mtDNA into the cell cytoplasm, and
possibly into the extracellular space [20]. Chronic neuroendocrine,
inflammatory, oxidative and metabolic stress may result in
mitochondrial dysfunction and mtDNA damage [21]. Downstream
effects of this stress–disease cascade involve cellular
dysfunction and senescence, and the release of ccf-mtDNA into
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the bloodstream, which in turn may have detrimental effects on
multiple organ systems via inflammatory mechanisms [21, 22].
Although this has not been well studied in psychiatric
settings, increased blood levels of free-circulating mtDNA
have been reported in a number of different somatic conditions
such as diabetes [23], cancers [15], and myocardial infarction [24]
and have been linked to more severe illness and worse outcome
[25].
Levels of ccf-mtDNA and cellular mtDNA-cn may have further
significance, as they also relate to cellular oxidative stress and
cellular senescence. MtDNA is highly vulnerable to oxidative stress
due to the lack of protective histones and limited DNA repair
mechanisms [26]. Antioxidant enzymes such as glutathione
peroxidase (GpX) are therefore needed in order to protect the
mitochondria and prevent cellular dysfunction [27]. Mitochondrial
integrity and bioenergetics are also related to nuclear DNA
senescence, due to a direct link between telomere shortening,
repression of peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1α) and diminished mitochondrial
biogenesis in certain tissues [28]. Thus, assessment of mtDNA, in
the cell-free circulation or in the intracellular compartment may
also inform on cellular stress and cellular senescence [21],
although the potential relevance of these interactions for MDD
is currently unclear.
Despite emerging evidence for a link between high mtDNA and
MDD [5, 29], there are inconsistent results across studies, [30–32]
and several unresolved issues remain. These include the extent to
which different measurements of mtDNA (e.g., leukocyte mtDNA-
cn vs. ccf- mtDNA) inter-correlate in subjects with and without
psychopathology, and how mtDNA levels in different compart-
ments relate to other biological markers implicated in MDD, such
as oxidative stress and indices of accelerated cellular aging.
Furthermore, most previous studies in MDD have included
subjects taking antidepressants or mood stabilizers, [5,29–31,33]
highlighting the importance of studying this in well-characterized
unmedicated MDD samples. Moreover, no previous studies have
investigated the relationship between leukocyte mtDNA-cn or ccf-
mtDNA and antidepressant treatment response. The purposes of
the present study were, therefore, to (i) investigate cellular and
circulating cell-free levels of mtDNA in a sample of well-
characterized, unmedicated, and somatically healthy MDD sub-
jects and healthy controls, (ii) test the relationship between
mtDNA and peripheral indices of oxidative stress and accelerated
cellular aging (telomere length), and (iii) determine if successful
antidepressant treatment is associated with changes in cellular
mtDNA-cn or ccf- mtDNA.
METHODS AND MATERIALS
Ethics statement
The Committee on Human Research of the University of California,
San Francisco (UCSF) approved the study protocol. All study
participants gave written informed consent to participate in this
study and were compensated for participating.
Baseline recruitment procedures and study participants
MDD (n = 50) outpatients and healthy controls (n = 55) were
recruited between 2011–2015 by flyers, bulletin board notices,
Craigslist postings, newspaper ads and, in the case of MDD
subjects, clinical referrals. Ccf-mtDNA measurements were missing
for two subjects, and PMBC mtDNA-cn was missing from two
subjects. All diagnoses, including MDD, were established using the
structured clinical interview [34] and were verified in a separate
diagnostic evaluation by a Board-certified psychiatrist. Depression
symptom severity was assessed in MDD subjects using the
Hamilton Depression Rating Scale (HDRS) [35]. All MDD subjects
had a minimum 17-item HDRS [35] score of 17. MDD subjects were
excluded if they met DSM-IV criteria (which were the extant
criteria in use at the time this study was conducted) for any of the
following: (i) bipolar disorder, (ii) alcohol or substance abuse
within the preceding 6 months, (iii) PTSD or an eating disorder
within 1 month of entering the study, and (iv) for any history of
psychosis outside of a major depressive episode (MDE), or the
presence of any psychotic symptoms during the current MDE.
Potential healthy controls were excluded for any history of DSM-IV
Axis-I diagnoses. All study participants were free of acute illnesses
or infections, inflammatory disorders, neurological disorders, or
any other medical conditions considered to be potentially
confounding (e.g., cancer, HIV, diabetes, history of cardiovascular
disease or stroke, etc.), as assessed by history, physical examina-
tions, and routine blood screening. All subjects were free of
psychotropic medications (including antidepressants), hormone
supplements, steroid-containing birth control or other potentially
interfering medications, including vitamin supplements above the
U.S. recommended daily allowances (e.g. >90 mg/day for Vitamin
C) and had not had any vaccinations for at least 6 weeks prior to
enrollment in the study. For the MDD subjects, short-acting
sedative-hypnotics were allowed as needed up to a maximum of
three times per week, but none within 1 week prior to blood
draws in the study. All subjects had to pass a urine toxicology
screen for drugs of abuse (marijuana, cocaine, amphetamines,
PCP, opiates, methamphetamine, tricyclic antidepressants, and
barbiturates) and a urine test for pregnancy in women of child-
bearing age on the same day as the blood draw.
Selective serotonin reuptake inhibitor (SSRI)-treatment
Nineteen MDD subjects underwent 8 weeks of protocol-based
open-label outpatient treatment with an SSRI antidepressant
(NCT00285935, https://www.clinicaltrials.gov/). In order to limit the
range of potential mechanism of action of antidepressants, the
choice of medication was limited to an SSRI. The decision for the
specific SSRI prescribed was based on clinical information such as
medical history, family history, prior medication history, subject
preference and potential side effects. Compliance and clinical
evaluations and assessments of drug tolerability were assessed by
a telephone check-in at the end of week 1 and an in-person
check-in at the end of week 4 and week 8, at which times pill
counts were performed. Plasma SSRI concentrations were
assessed at the week 4 and week 8 visits to evaluate medication
compliance. Primary outcome measure was severity of depressive
symptoms, assessed by means of the HDRS. HDRS ratings were
repeated at the end of treatment (week 8). Twelve subjects were
treated with sertraline (mean ± SD dose in mg = 142 ± 36), two
with fluoxetine (mean ± SD dose in mg = 35 ± 7), two with
citalopram (mean ± SD dose in mg = 35 ± 7), and three with
escitalopram (mean ± SD dose in mg = 13 ± 6). Medication
dosages were increased over the course of treatment per pre-
specified protocol as tolerated and as warranted by clinical
response. Sertraline dosing began with 25 mg per day and
increased to a maximum of 200 mg per day; fluoxetine and
citalopram dosing began with 10mg per day and increased to a
maximum of 40 mg per day; escitalopram dosing began with 10
mg per day and increased to a maximum of 20mg per day.
“Responders” were defined as subjects with greater than or equal
to 50% improvement on HDRS ratings at week 8 compared to
baseline. There was no significant difference in final SSRI dose
(sertraline equivalents) between responders and non-responders
(p = 0.59), and all subjects (responders and non-responders) had
plasma SSRI levels within expected reference ranges.
Blood sampling and DNA extraction
Venipuncture was performed at approximately 10:00 am at the
UCSF Clinical and Translational Science Institute, after 12 h of
fasting (except water). Plasma was collected with a lavender EDTA
vacutainer tube. Tubes were spun at 1500×g for 10min and 4° C,
and plasma was removed, aliquoted into tubes and frozen at −80°
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C until used. PBMCs were prepared from whole blood by ficoll
centrifugation [36] and were frozen at −80 °C. DNA was extracted
from frozen PBMCs using commercially available reagents (Pure-
gene, Gentra Systems, Qiagen, Valencia, CA). DNA quality and
quantity were assessed using Nanodrop spectrophotometer and
random samples were also assessed by agarose gel electrophor-
esis to assess DNA integrity.
Measurement of mtDNA-cn in PBMCs
The mtDNA-cn in PBMCs was determined by multiplex real-time
polymerase chain reaction (PCR) assay simultaneously quantifying
genomic mitochondrial (ND1) and nuclear (Ribonuclease P)
amplicons, as described elsewhere [37]. Lab personnel who
performed the assay were blind to demographic and clinical data.
Measurement of ccf-mtDNA in plasma
The isolation and quantification of mtDNA in plasma samples has
been previously described [16]. Briefly, the thawed plasma
samples were centrifuged for 10 min at 10,000×g to remove cells
and cellular debris.
DNA were isolated from 200 μl of the supernatant using the QIAmp
96 DNA Blood Kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s instruction for blood and body-fluid protocol. The
isolated DNA was then eluted in 200 μl and quantified using
spectrophotometric analysis at 260/280 nm in a Nanodrop (ND-1000
Spectrophotometer v 3.7.1, Waltham, MA, USA). The quantitative
analysis of ccf-mtDNA was performed using quantitative real time
polymerase chain reaction. The experiment was run once in triplicate
reactions. A dilution series consisting of the purified PCR product from
a healthy control subject, not taking part in the present study, was
constructed and used to create a standard curve. The DNA sequence
of the PCR-fragment was determined before the dilution series was
carried out. The different crossing-point values from the unknown
samples were compared with the standard curve, and the
corresponding number of mitochondrial units was calculated. The
amount of DNA (g μl−1) was divided with the size of the PCR-fragment
(161 bp) and the molar mass per base pair (gmol−1). The product was
finally multiplied with Avogadro’s constant.
Mitochondrially encoded NADH: Ubiquinone Oxidoreductase
Core Subunit 2 (MT-ND2) gene was amplified using the following
primers (Life Technologies, Pailsey, UK): Forward primer: [CACACT-
CATCACAGCGCTAA]; reverse primer: [GGATTATGGATGCGGTTGCT].
In order to verify the data, the assay was also completed with
another target, the mtDNA-encoded NADH: Ubiquinone Oxidor-
eductase Core Subunit 1 (MT-ND1) gene. This gene was amplified
in the same way as above, but using the following primers (Life
Technologies, Paisley, UK): Forward primer: [CCCTAAAACCCGCCA-
CATCT]; reverse primer: [CCGATCAGGGCGTAGTTTGA]. Both ampli-
cons were strongly correlated ( r= 0.73, p < 0.001), indicating that
inter-individual mtDNA sequence variation did not affect our
ability to detect ccf-mtDNA levels.
The PCR reactions were carried out using SYBR Green Technology
(Thermo Fisher Scientific, Waltham, MA, USA). Each 20 μl reaction
contained 5 μl of template, 1 μl of each primer (10 μM), 10 μl SYBR
MIX (2 × Sensifast, Bioline, London, UK) and 3 μl of nuclease-free
water. Each reaction was run in triplicate on a LC480 (LightCycler from
Roche, Mannheim, Germany) using the following program:
Initial denaturation at 95 °C for 10 min, followed by 45 cycles
consisting of 95 °C in 10 s. For melting, 65 °C for 10 s annealing and
72 °C for 11 s extension. The program ended with a melting curve
analysis measuring fluorescence continuously from 60 to 97 °C.
Measurement of GpX
Glutathione peroxidase activity (BioVision, Inc., Milpitas, California,
USA) was measured in duplicate from plasma, using a colorimetric
assay according to the instructions from the manufacturer. The
coefficient of variation was < 10% and LLOQ was 0.5 nmol NADPH/
ml/min.
Measurement of PBMC telomere length
The telomere length measurement assay is adapted from the
published original method by Cawthon [38, 39].
The telomere thermal cycling profile consists of:
Cycling for T(telomic) PCR: 96 °C for 1 min; denature at 96 °C for
1 s, anneal/extend at 54 °C for 60 s, with fluorescence data
collection, 30 cycles.
Cycling for S (single copy gene) PCR: PCR: 96 °C for 1 min;
denature at 95 °C for 15 s, anneal at 58 °C for 1 s, extend at 72 °C
for 20 s, 8 cycles; followed by denature at 96 °C for 1 s, anneal at
58 °C for 1 s, extend at 72 °C for 20 s, hold at 83 °C for 5 s with data
collection, 35 cycles.
The primers for the telomere PCR are tel1b [5′-CGGTTT
(GTTTGG)5GTT-3′], used at a final concentration of 100 nM, and
tel2b [5′-GGCTTG(CCTTAC)5CCT-3′], used at a final concentration of
900 nM. The primers for the single-copy gene (human beta-globin)
PCR are hbg1 [5′-GCTTCTGACACAACTGTGTTCACTAGC- 3′], used at
a final concentration of 300 nM, and hbg2 [5′-CACCAACTTCATC-
CACGTTCACC-3′], used at a final concentration of 700 nM. The final
reaction mix contains 20 mM Tris-HCl, pH 8.4; 50 mM KCl; 200 mM
each dNTP; 1% DMSO; 0.4× Syber Green I; 22 ng E. coli DNA per
reaction; 0.4 Units of Platinum Taq DNA polymerase (Invitrogen
Inc.) per 11 µl reaction; ~6 ng of genomic DNA. Tubes containing
26, 8.75, 2.9, 0.97, 0.324 and 0.108 ng of a reference DNA (pooled
human genomic DNA from leukocytest) are included in each PCR
run so that the quantity of targeted templates in each research
sample can be determined relative to the reference DNA sample
by the standard curve method. The same reference DNA will be
used for all PCR runs.
To control for inter-assay variability, eight control DNA samples
are included in each run. In each batch, the T/S ratio of each
control DNA is divided by the average T/S for the same DNA from
10 runs to get a normalizing factor. This is done for all eight
samples and the average normalizing factor for all eight samples is
used to correct the participant DNA samples to get the final T/S
ratio. The T/S ratio for each sample will be measured twice. When
the duplicate T/S value and the initial value vary by more than 7%,
the sample will be run the third time and the two closest values
were reported.
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) v.22 (IBM
Corp., Armonk, NY) was used for statistical calculations. All tests
were two-tailed with an alpha = 0.05. Non-normally distributed
variables were log-transformed to achieve normality, as was the
case for both ccf-mtDNA and PBMC mtDNA-cn. In cases when log
transformation was insufficient (viz., baseline HDRS scores), we
used Blom transformation, a statistical procedure replacing each
raw score with its rank value and adjusting the scale distances
between the ranks to achieve a normal distribution. As GpX was
assayed in two separate batches, we combined z-scores from both
batches into one variable for analyses. Correlations were tested
using Pearson’s r, adjusting for covariates using partial correla-
tions. Group comparisons are presented as unadjusted (Student’s
t-test) and adjusted (ANCOVA) analyses. Repeated measures
ANOVAs were used to test the time x group interaction on the
changes in mtDNA between baseline and week 8 in SSRI
responders and non-responders. Covariates were age, sex, body
mass index (BMI) and smoking status, analyses are presented as
unadjusted and adjusted.
RESULTS
Demographic characteristics
Demographic characteristics of MDD subjects and controls and of
SSRI responders and non-responders are presented in Table 1.
There were no significant between-group differences with
regard to age, and sex. Compared to controls subjects, MDD
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subjects had higher BMI, and were more likely to be current
tobacco users. SSRI non-responders had higher BMI than SSRI
responders (p = 0.054). After 8 weeks of SSRI treatment, HDRS
score was 6.8 ± 2.4 (mean ± SD) for responders and 14.6 ± 4.8
(mean ± SD) for non-responders. For five subjects, this was the first
depressive episode, and all other subjects had suffered from
previous depressive episodes (median total number of depressive
episodes = 4).
MtDNA at baseline in MDD subjects vs. controls, and correlations
with depression symptom severity ratings
MDD subjects had significantly higher levels of ccf-mtDNA
compared to healthy controls (mtDNA copies per µl plasma, log-
transformed, mean ± SD: 12.0 ± 1.2 vs. 11.0 ± 1.1, t = 4.8, p <
0.00001, Cohen’s d = 0.93). MDD subjects did not differ signifi-
cantly from controls in mtDNA-cn measured in PBMCs (mtDNA
copies per cell, log-transformed, mean ± SD: 5.1 ± 0.4 vs. 5.0 ± 0.4,
t = 0.7, p = 0.48, Cohen’s d = 0.14). After adjusting for age, sex, BMI
and smoking, group difference in cell-free plasma mtDNA
remained significant (F = 20.6, p = 0.00002), while PMBC mtDNA-
cn remained non significant (F = 0.2, p = 0.65). Baseline mtDNA
measurements (ccf-mtDNA and PBMCs) in MDD subjects and
controls are shown in Fig. 1. In order to verify these data, we also
an analyzed ccf-MtDNA using another target (MT-ND1). This
yielded similar results and confirmed the difference in ccf-mtDNA
levels between MDD subjects and controls (p < 0.001, Cohen’s d =
0.78).
Within the MDD subjects there were no significant correlations
between HDRS scores at baseline and mtDNA levels in cell-free
plasma (r = 0.03, p = 0.86), or PBMC (r = −0.27, p = 0.064). Number
of depressive episodes did not correlate significantly with either
PBMC mtDNA-cn (r = 0.21, p = 0.14) or plasma ccf-mtDNA (r =
−0.12, p = 0.42).
MtDNA levels after 8 weeks of SSRI treatment in a subsample of
MDD subjects, preliminary analyses
Ccf (n = 19) and PBMC (n = 18) mtDNA were available from a
subset of MDD subjects before and after 8 weeks of SSRI
treatment, as described above. MtDNA data from healthy controls
were only available at baseline. A significant time (baseline vs.
week 8) × group (SSRI responders vs. non-responders) interaction
was observed for ccf-mtDNA (unadjusted F = (1,17) 4.43, p = 0.05;
adjusted F = (1,13) 6.47, p = 0.02), but not for PBMC mtDNA-cn (all
p > 0.4). After Bonferroni correction, non-responders showed a
significant increase in ccf-mtDNA between baseline and week 8
(unadjusted p = 0.04; adjusted p = 0.02), while this was not seen in
responders (all p > 0.32). In cross-sectional analyses, ccf-mtDNA
was higher in non-responders compared to responders at week 8
at trend level (unadjusted p = 0.06; adjusted p = 0.08), but did not
significantly differ at baseline (all p > 0.13). Further, SSRI non-
Table 1. Demographic and clinical characteristics of subjects with MDD and controls and in SSRI responders and non-responders
Controls N= 55 MDD N= 50 P-value Responders N= 11 Non-responders N= 8 P-value
Sex (f/m) 33/22 27/23 0.54 8/3 5/3 0.64
Age (Years; mean± SD) 37.6± 13.9 39.6± 14.7 0.47 39.2± 12.6 39.0± 14.9 0.98
BMI (kg/m2; mean± SD) 24.4± 4.9 26.1± 4.5 0.07 26.2± 5.4 30.1± 2.7 0.05
Current tobacco users (n) 3 13 < 0.01 3 2 0.91
HDRS score at baseline (mean± SD) N/A 20.2± 3.3 N/A 19.8± 3.0 19.6± 4.0 0.91
HDRS Hamilton Depression Ratting Scale, BMI body mass index
Fig. 1 Circulating cell-free mitochondrial DNA (Ccf-mtDNA) and peripheral blood mononuclear cell (PBMC) mtDNA copy number in MDD
subjects and controls. Data were log-transformed. Error bars indicate ±1 SD
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responders had significantly higher ccf-mtDNA levels at week 8
compared to healthy control levels at baseline (p < 0.001), whereas
no significant difference was seen between SSRI responders at
week 8 and healthy controls at baseline (p = 0.37). Adjusting for
age, sex, BMI and smoking did not substantially alter these
findings. Change in ccf-mtDNA between baseline and week 8 in
responders and non-responders is shown in Fig. 2.
At week 8, there were no significant correlations between HDRS
scores and plasma cell-free mtDNA levels, or in PBMC mtDNA-cn
(all p > 0.2). Absolute change in HDRS scores were not correlated
with absolute change in either ccf-mtDNA or PBMC mtDNA-cn
(all p > 0.1)
Correlations between mtDNA and other biomarkers
Across all subjects, ccf-mtDNA and PBMC mtDNA-cn measure-
ments were not inter-correlated (unadjusted: r = −0.02, p = 0.87;
adjusted: r = −0.03, p = 0.79).
Across all subjects, Ccf-mtDNA, but not PBMC mtDNA-cn, was
positively correlated with antioxidant enzyme glutathione perox-
idase (ccf-mtDNA unadjusted and adjusted: r = 0.32, p = 0.001;
PBMC mtDNA-cn unadjusted and adjusted: r = −0.12, p = 0.26).
Conversely, PBMC mtDNA-cn, but not ccf-mtDNA, was positively
correlated with PBMC telomere length (PBMC mtDNA-cn unad-
justed: r = 0.28, p = 0.005, adjusted: r = 0.38, p = 0.0001; ccf-mtDNA:
unadjusted: r = 0.08, p = 0.42, adjusted: r = 0.11, p = 0.27).
Overall, these correlations indicate that about 10% in the
variance of ccf-mtDNA and PBMC mtDNA-cn (bivariate
correlations) is accounted for by differences in antioxidant activity
and telomere length, respectively.
Figs. 3 and 4 show these correlations in MDD and control
subjects separately.
DISCUSSION
Our results show that ccf-mtDNA is significantly higher in un-
medicated MDD subjects compared to healthy controls, but that
cellular (PBMC) mtDNA-cn does not significantly differ between
groups. PBMC mtDNA-cn likely reflects intracellular mtDNA
content and bioenergetics [6], independent of apoptosis; how-
ever, ccf-mtDNA is likely released from cells during cellular stress
[19, 40] and does not contribute to cell energetics. Consistent with
the idea that they may reflect different processes, ccf-mtDNA and
cellular PBMC measures of mtDNA-cn were not significantly
correlated. Additionally, the present study found that ccf-mtDNA
levels further increased in non-responders to SSRI treatment over
the 8-week course of treatment, whereas ccf-mtDNA levels in
responders did not significantly change. After 8 weeks of SSRI
treatment, ccf-mtDNA remained significantly elevated in non-
responders compared to baseline levels of controls, whereas, at
the same time point, there was no significant difference between
responders and baseline levels of controls. In contrast, cellular
(PMBC) mtDNA-cn did not significantly change over the course of
SSRI treatment in either responders or non-responders. These data
suggest that ccf-mtDNA and cellular PBMC mtDNA-cn reflect
different cellular processes and that the former may be more
reflective of certain aspects of MDD pathophysiology and of the
response to SSRI antidepressants.
Studies of leukocyte mtDNA-cn in MDD have yielded inconsistent
results, and only two previous studies have examined ccf-mtDNA in
psychiatric samples. In the largest study in MDD to date, Cai et al.
showed that greater mtDNA-cn in saliva and in blood leukocytes
was associated with MDD [5]. The same group later confirmed, in a
longitudinal study, that MDD subjects have higher cellular mtDNA-
cn compared to controls over 8 weeks of antidepressant treatment.
Across all time points, but not cross-sectionally, mtDNA-cn was
positively correlated with depression severity [29]. Other studies
have, however, reported lower [30] or unchanged [31] leukocyte
mtDNA-cn in MDD compared to controls. Moreover, two
population-based studies reported negative correlations between
leukocyte mtDNA-cn and depressive symptoms [41, 42], while a
recent longitudinal study did not find any between-person or
within-person associations between depressive symptoms and
leukocyte mtDNA-cn [32]. In regards to other affective disorders,
one study on euthymic bipolar disorders showed lower leukocyte
mtDNA-cn compared to controls [33], while another study on
subjects with bipolar disorder in a depressive episode did not find a
Fig. 2 Change in circulating cell-free mitochondrial DNA (ccf-
mtDNA) (mean + SEM) between baseline and week 8 in SSRI
responders and non-responders. Data were log-transformed
Fig. 3 Circulating cell-free mitochondrial DNA (ccf mtDNA) (log-
transformed) plotted against glutathione peroxidase activity (GpX)
(z-scores) in MDD subjects and healthy controls. Pearson’s r= 0.32, p
= 0.001
Fig. 4 Peripheral blood mononuclear cell (PBMC) telomere length
plotted against PBMC mitochondrial DNA-copy number (mtDN-cn)
(log-transformed) in MDD subjects and healthy controls. Pearson’s r
= 0.28, p= 0.005
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significant difference in mtDNA-cn compared to controls, either
before or after lithium treatment [43]. Reasons for the discrepancy
in findings in these studies of cellular mtDNA-cn are not known, but
could involve medication status of the subjects, different sample
sizes across studies, somatic co-morbidities, differences in age,
ethnicity or gender composition, differences in phenotypes (e.g.,
MDD diagnosis vs. depressive symptoms) or methodological
differences (e.g., whole blood vs. isolated PBMCs). We note that
our study might have been underpowered to detect a significant
relationship between cellular, PBMC, mtDNA-cn and an MDD
diagnosis, since some previous studies demonstrating such an
effect had larger samples sizes [5, 29].
Only two studies have previously examined ccf-mtDNA in a
psychiatric population. Our research group previously reported
that ccf-mtDNA is strongly increased (Cohen’s d = 2.55–4.01) in
suicidal individuals (whether or not with MDD diagnoses)
compared to healthy controls [16]. The present study only
included subjects with MDD, and none were actively suicidal.
In contrast to our study, Kageyama et al. recently reported lower
ccf-mtDNA levels in MDD subjects compared to controls [17].
Differences in subject recruitment, blood sampling and statistical
modeling may have contributed to the divergent findings. For
example, Kageyama et al. did not actively exclude subjects with
potentially confounding medical conditions, and they did not
adjust for the effects of smoking or BMI on mtDNA.
Whereas cellular mtDNA-cn is a marker of mitochondrial
biogenesis and energetics [6], ccf-mtDNA is believed to be
released during cellular injury [19, 40]. Ccf-mtDNA molecules are
subsets of so called damage-associated molecular patterns, which
may have detrimental downstream effects involving immune
activation [22]. Consistent with their reflecting different aspects of
mitochondrial/cellular physiology, ccf-mtDNA was not significantly
correlated with cellular (PBMC) mtDNA-cn in our study. The
differential significant correlations we observed between ccf-
mtDNA and PBMC mtDNA-cn versus antioxidant enzyme activity
and telomere length, respectively, are also consistent with these
functional differences.
During states of increased cellular and oxidative stress, genes
encoding antioxidant enzymes, such as GpX, may increase their
expression in an attempt to restore cellular homeostasis [44].
Oxidative stress can damage cellular integrity and, if unchecked,
can lead to cellular endangerment or apoptosis, both of which can
lead to mtDNA extrusion from the cell or release into the blood,
increasing ccf-mtDNA. In fact, infusions of the anti-oxidant Vitamin
C were observed to diminish ccf-mtDNA in Intensive Care Unit
patients [45]. We had predicted an inverse relationship between
GPx levels and ccf-mtDNA, although the opposite was found.
Although speculative and in need of replication, our finding of a
direct correlation between ccf-mtDNA levels and GpX activity may
reflect a compensatory attempt to, ineffectively, upregulate the
body’s antioxidant defense mechanisms due to cellular stress. This
hypothesis is in line with several preclinical studies reporting that
GpX may protect against apoptotic cell death [44] and oxidative
stress induced mtDNA damage [27].
Telomere shortening can reciprocally lead to cellular mitochon-
drial endangerment and diminished mitochondrial biogenesis via
diminution of PGC-1α, the master regulator of mitochondrial
biogenesis [28]. Telomeres become shorter due to each cell
division, DNA damage, and exposure to oxidative stress [13]. In our
study, PBMC mtDNA-cn was correlated with PBMC telomere
length, a marker of cellular aging. This is in line with several
previous studies reporting a positive association between mtDNA
(measured in leukocytes) and telomere length [32, 41, 46, 47].
Oxidative stress and telomere shortening can both be induced
by mitochondrial dysfunction, or mitochondrial allostatic load [21].
Although mitochondrial function was not measured directly here,
the present data suggest that ccf-mtDNA may represent a more
sensitive marker of cellular damage or cellular stress, not reflective
of cellular mtDNA content or cellular energetics. The underlying
mechanisms behind cellular stress and mitochondrial dysfunction
in mood disorders are not yet fully understood, but might involve
a wide array of pathophysiological processes. For instance,
elevated stress and increased levels of pro-inflammatory cytokines
may lead to accumulation of tryptophan catabolites (TRYCATS) via
activation of the kynurenine pathway. TRYCATS may alter
mitochondrial function both directly and via the metabolism of
the endogenous antioxidant melatonin [48], with potential
relevance for the pathophysiology of MDD.
In several of the previous studies investigating the relationship
between mtDNA and depressive symptoms, a high proportion of
depressed subjects was using antidepressant medications [5, 30,
31, 41, 42]. The participants in our study were free of any
psychiatric medication for a period of at least 6 weeks prior to
enrollment. This is important since experimental studies have
shown that antidepressants may cause alterations in mitochon-
drial function [49], e.g., via inhibition of mitochondrial enzyme
complexes [50], and uncoupling of oxidative phosphorylation [51].
Data from experimental studies suggest that antidepressants may
have both pro-apoptotic [52], and anti-apoptotic properties [53],
and that some of these effects may be mediated via mitochondria-
associated pathways [54]. Interestingly, Djordejevic et al. found
that fluoxetine induced apoptosis in rat liver cells, but these
alterations were more pronounced in stressed animals compared
to non-stressed animals [52]. Based on these data, we speculate
that antidepressants may have pro-apoptotic or anti-apoptotic
effects depending on symptom trajectory during the treatment
course. This is in line with our observation that ccf-mtDNA
continued to be higher in those subjects who did not respond to
SSRI treatment, whereas there was no difference in ccf-mtDNA
between SSRI responders and healthy controls. We note, however,
that there was no significant difference in ccf-mtDNA between
SSRI responders and non-responders at baseline. Thus, our data
do not support the usefulness of ccf-mtDNA as a predictor of
antidepressant treatment response, although larger samples are
needed to draw any firm conclusions about this.
Strengths of the present study include (i) the simultaneous
assessment of ccf-mtDNA as well as PBMC mtDNA-cn, (ii) the use
of physically healthy and well-characterized subjects, (iii) the
minimum 6-week medication-free period, and (iv) the exclusion
of concomitant medications that could influence our results.
Further, this is among the first studies to measure mtDNA, either
cellular or cell-free plasma, before and after antidepressant
treatment. However, the relatively small number of subjects
receiving antidepressants yielded low power to test the relation-
ship between ccf-mtDNA, cellular mtDNA-cn and SSRI response.
Therefore, our results pertaining to the association between
mtDNA levels and SSRI treatment response should be considered
preliminary and in need of replication in larger samples. There are
also several methodological factors that could have influenced
our results. For example, the apparent increase of mtDNA in MDD
subjects could be secondary to platelet or leukocyte lysis during
the blood sampling, leading to subsequent release of mtDNA into
the plasma. However, the blood sampling procedures for MDD
subjects and controls was identical, so we believe that it is very
unlikely that such methodological factors may have confounded
our findings. Finally, another important limitation of our study is
that mtDNA was measured in the peripheral blood, thus we were
not able to determine if these biological markers are related to
brain pathology in MDD. This would be an important area of
future studies since we are not aware of any previous reports
testing the relationship between peripheral measurements of
mtDNA and brain imaging indices. Interestingly though, one
recent post-mortem study [55] found alterations in mtDNA in the
dorso-lateral prefrontal cortex of suicide completers, suggesting
that changes in mtDNA might be relevant also for brain
pathology.
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In conclusion, our results indicate that ccf-mtDNA is a
physiologically distinct marker from cellular (PBMC) mtDNA-cn.
Even after adjustment for potential confounders, ccf-mtDNA was
elevated in un-medicated MDD and continued to increase in
subjects refractory to an 8-week SSRI treatment, whereas patients
whose depressive symptoms substantively decreased post-
treatment did not demonstrate changes in ccf-mtDNA levels.
Together, these data suggest that elevated ccf-mtDNA may be a
novel biological correlate of MDD and responsive to treatment,
although the possible mechanistic relationship of this marker to
depressive pathophysiology, and whether this is a state- or trait-
related marker, remain unknown. Given previous inconsistencies
in reported associations between intracellular leukocyte mtDNA-
cn and depression, our findings point to mtDNA in cell-free
plasma as a promising biological correlate of depression. The
specificity of these findings for MDD is also unknown and will
require further testing.
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